| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2c66433dc482df3c06fb118725d5c325 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 |
| filingDate |
2012-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cece0716c1c292089029e3d53db7c3c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d87bebc51b5108eb7dfdb0868b0b768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33b4e13d2c6daf6c17451f0453110ac2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_982b88a6ec85b37e4d9ff750c9a14a40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e53c4cf22a3fd29229cfd684e3668b2c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c39cb1664b3acacdebf43f491bdd74f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25735be443faa34257ba3c80e7952f0f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad7043d0d63abeaf46c8b55043436966
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28246a6bbae23fb56a3daf213c21983d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07b8f8019bc704471e47aff5bb87ab5b |
| publicationDate |
2014-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2519756-C1 |
| titleOfInvention |
Method for prevention of intrahepatic portal hypertension in patients following hepatectomy |
| abstract |
FIELD: medicine. n SUBSTANCE: invention may be used for prevention of intrahepatic portal hypertension (IPH) in residual tissue of liver in patiens after hepatectomy (HE) of the different volume. That is ensured by an ultrasonography to determine a spleen area to be taken as an original size with underlying standard postoperative therapy in the first postoperative hours. Serotonine adipinate is administered intravenously drop-by-drop in a dose of 5-10 mg an hour with a spleen size monitored periodically. Administering the preparation is terminated if observing a decrease of the spleen area by not less than 10% of the original size. n EFFECT: improved blood circulation in the residual tissue of the liver, prevented IPH decreasing thereby a mortality of the given group of patients. n 2 ex, 1 tbl |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2650044-C1 |
| priorityDate |
2012-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |